US-based healthcare group NorthShore University HealthSystem has partnered with surgical robotics company Procept Biorobotics to treat patients with benign prostatic hyperplasia (BPH), a prostate condition that affects millions of men in the US.
NorthShore has installed PROCEPT BioRobotics’ AquaBeam Robotic System, a surgical robotic system designed to facilitate minimally invasive urologic surgery, at its Highland Park Hospital.
Go deeper with GlobalData
The hospital is the first in the US to install two AquaBeam Robotic Systems, which it uses to administer the aquablation therapy procedure for BPH.
NorthShore chief of urology and clinical professor at the University of Chicago Dr Brian Helfand said: “Aquablation therapy has revolutionised the way we treat BPH.
“Its exceptional clinical outcomes, including significant improvements in urinary symptoms and preservation of sexual function, along with low complication rates have led me to transition nearly all my BPH cases to this transformative technology.
“We have become a national and international destination for this surgery and have treated men from all over the US and six countries.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAquablation is a robotic therapy that uses a heat-free water jet to remove prostate tissue.
The procedure is designed to minimise side effects such as ejaculatory function while preserving erectile function and continence.
The technology uses real-time ultrasound imaging to allow customised treatment planning according to each patient’s unique anatomy.
PROCEPT BioRobotics said the therapy has shown consistent results across different prostate anatomies as demonstrated by clinical trials, including the WATER and WATER II trials.
PROCEPT BioRobotics executive vice-president and chief commercial officer Sham Shiblaq said: “NorthShore’s installation of two additional AquaBeam systems highlights the ongoing shift in the standard of care for BPH treatment.
“Aquablation is poised to replace traditional procedures like TURP (transurethral resection of the prostate) nationwide, thanks to its consistent and long-lasting outcomes and superior safety profile, regardless of prostate size, shape or surgeon experience.”
